|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,270,000 |
Market
Cap: |
287.50(M) |
Last
Volume: |
197,427 |
Avg
Vol: |
196,884 |
52
Week Range: |
$13.82 - $26.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
10,600 |
117,800 |
Total Buy Value |
$0 |
$0 |
$183,361 |
$2,088,813 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
10 |
21 |
Total Shares Sold |
0 |
0 |
0 |
27,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-12-18 |
4 |
AS |
$5.67 |
$33,992 |
D/D |
(6,000) |
3,534 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-12-18 |
4 |
OE |
$3.04 |
$18,240 |
D/D |
6,000 |
9,534 |
|
- |
|
Varian John |
CEO |
|
2013-12-16 |
4 |
AS |
$5.44 |
$54,372 |
D/D |
(10,000) |
148,739 |
|
- |
|
Varian John |
CEO |
|
2013-12-16 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
158,739 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-12-02 |
4 |
AS |
$6.00 |
$120,002 |
D/D |
(20,000) |
42,017 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-12-02 |
4 |
OE |
$1.69 |
$33,800 |
D/D |
20,000 |
58,682 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-11-27 |
4 |
AS |
$4.54 |
$21,320 |
D/D |
(4,696) |
3,534 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-11-27 |
4 |
OE |
$3.04 |
$14,276 |
D/D |
4,696 |
8,230 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-11-18 |
4 |
AS |
$4.08 |
$5,317 |
D/D |
(1,304) |
3,534 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-11-18 |
4 |
OE |
$2.36 |
$3,077 |
D/D |
1,304 |
4,838 |
|
- |
|
Varian John |
CEO |
|
2013-11-15 |
4 |
AS |
$4.13 |
$41,329 |
D/D |
(10,000) |
148,739 |
|
- |
|
Varian John |
CEO |
|
2013-11-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
158,739 |
|
- |
|
Varian John |
CEO |
|
2013-11-13 |
4 |
S |
$3.89 |
$218,807 |
D/D |
(56,214) |
92,525 |
|
- |
|
Varian John |
CEO |
|
2013-11-13 |
4 |
AS |
$3.91 |
$214,938 |
D/D |
(54,932) |
148,739 |
|
- |
|
Varian John |
CEO |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,665 |
201,216 |
|
- |
|
Wyszomierski Jack L |
Director |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
11,797 |
|
- |
|
Bowes William K Jr |
Director |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
12,868 |
|
- |
|
Walbert Timothy P |
Director |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
11,797 |
|
- |
|
Van Ness W Denman |
Director |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,876 |
16,902 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-11-13 |
4 |
S |
$3.91 |
$32,660 |
D/D |
(8,346) |
42,017 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,652 |
50,363 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2013-11-13 |
4 |
S |
$3.91 |
$48,244 |
D/D |
(12,331) |
22,085 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2013-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,596 |
34,416 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-10-18 |
4/A |
AS |
$4.71 |
$24,725 |
D/D |
(5,254) |
3,534 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2013-10-18 |
4 |
AS |
$4.71 |
$3,511 |
D/D |
(746) |
8,788 |
|
- |
|
597 Records found
|
|
Page 17 of 24 |
|
|